BLIS ThroatGuard Australian Product of the Year
22 November 2019
BLIS ThroatGuard Australian Probiotic Product of the Year
Sydney, Australia, November 2019 – BLIS PROBIOTICS ThroatGuard has been awarded Probiotic
Product of the Year by Product of the Year
1
(POY).
POY is the world’s largest consumer-voted award for product innovation. Established over 30 years
ago in France, POY currently operates in over 40 countries with the same purpose: Guide consumers
to the best products in their market and reward manufacturers for quality and innovation.
BLIS PROBIOTICS ThroatGuard, containing BLIS K12™, is an oral targeted probiotic, discovered by
Professor Emeritus John Tagg while at the University of Otago, New Zealand. Unlike most probiotics,
which work in the gut, BLIS PROBIOTICS ThroatGuard targets and protects the gateway to the body –
the mouth and throat. It is a product that has brought innovation to the Australian probiotic category
in 2019.
“iNova Pharmaceuticals, in partnership with Blis Technologies, is thrilled to accept this award in
recognition of the hard work that went into launching the product in the Australian market in 2019”,
said Andrew Jenkin, iNova’s Managing Director for Australia and New Zealand. “The product launched
with a comprehensive marketing program. Together with our Difflam range, the BLIS PROBIOTICS
range cements iNova’s position as a leader in throat health. Winning the Product of the Year Award
gives us yet another tool to amplify awareness and build consumer trust.”
Blis Technologies CEO Brian Watson said ‘This is a great recognition of the Australian launch activity
lead by our distribution partner, iNova Pharmaceuticals, but also further recognition of the unique
and differentiated BLIS range”
Ends
For further information, please contact:
Brian Watson
CEO
+64 27 705 9133
1
Winner Probiotic Category. Survey of 10,000 people by Nielsen.
Blis Technologies Ltd. 81 Glasgow Street, South Dunedin, 9012, New Zealand. Ph: 03 474 0988
www.blis.co.nz; info@blis.co.nz
About iNova Pharmaceuticals
iNova Pharmaceuticals is a multinational pharmaceutical and consumer healthcare company that markets and sells
a wide range of market-leading products, primarily in the areas of weight management, cough and cold, throat,
skin care and natural health.
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation
with evidence-based research and the highest quality production controls enables the delivery of probiotic
solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and
gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More
information about Blis Technologies Ltd can be found at www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- FSF — Fonterra Shareholders' Fund: Fonterra announces FY19 annual results and new strategy2019-09-25
“OUR YEAR THAT'S BEEN Nutrition Our products can help improve the health and wellbeing of people around the world. Here’s a snapshot of how we helped this year. Soprole™ Protein + In Chile, we have continued to expand our range of Soprole™ Protein+ products this year with fou…”
- FCG — Fonterra Co-operative Group Limited: Fonterra announces FY19 annual results and new strategy2019-09-25
“OUR YEAR THAT'S BEEN Nutrition Our products can help improve the health and wellbeing of people around the world. Here’s a snapshot of how we helped this year. Soprole™ Protein + In Chile, we have continued to expand our range of Soprole™ Protein+ products this year with fou…”
- EBO — EBOS Group Limited: Half Year Results2020-02-19
“4 available via the Australian wholesale network which is a great outcome for patients ensuring they will receive medicines in a timely and efficient manner”, Mr Cullity said. Animal Care Animal Care A$ 31 December 2019 31 December 2018 Growth…”